Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.
1 report, 1 independent
Updated Oct 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
-
Royal Bank of Canada
financial institution in Canada
Related events
- Cantor Fitzgerald and Royal Bank of Canada updated their ratings and positions regarding Rezolve Ai.
- Cantor Fitzgerald reiterated an overweight rating for Sterling Infrastructure on November 1, 2026.
- Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Various financial institutions, including Royal Bank of Canada, Bank of America, Raymond James Financial, TD Cowen, Cantor Fitzgerald, and MarketBeat, issued rating and price target updates regarding United Therapeutics on July 10, 2026.